Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?

Clinical Pharmacokinetics

Volumn 33, Issue 6, 1997, Pages 403-416

  Davies, Neal M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; CYCLOOXYGENASE 2; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; SERUM ALBUMIN; ALKANONE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; KIDNEY FAILURE; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYNOVIAL FLUID; DOSE RESPONSE; HUMAN; INTESTINE ABSORPTION; METABOLISM; PROTEIN BINDING; REVIEW; TISSUE DISTRIBUTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; PROTEIN BINDING; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

EID: 0031454049     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733060-00001     Document Type: Article

References (45)

1. Jeremy JY, Mikhailidis DP, Barradas MA. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheum 1990; 29: 116-9
2. Goudie AC, Gaster LM, Lake AW, et al. 4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds. J Med Chem 1978; 219 (12): 1260-4
3. Friedel HA, Todd PA. Nabumetone: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. Drugs 1988; 35 (5): 504-24
4. Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993; 45 (1): 131-6
5. Ray JE, Day RO. High-performance liquid chromatographic determination of a new anti-inflammatory agent, nabumetone, and its major metabolite in plasma using fluorimetric detection. J Chromatogr 1984; 336: 234-8
6. Maleev A, Vlahov V, Gruev I, et al. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. Int J Clin Pharmacol Ther Toxicol 1986; 24 (8): 425-9
7. Torre D, Sampietro C, Maggiolo F. Blood and tissue fluid levels of a new non- steroidal anti-inflammatory preparation of nabumetone. J Int Med Res 1987; 15: 368-73
8. Daigneault EA, Ferslew KE, Stanton P. Bioequivalence study of nabumetone: tablet versus suspension. Am J Med 1987; 83 Suppl. 4B: 11-4
9. Kendall MJ, Chellingsworth MC, Jubb R, et al. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. Eur J Clin Pharmacol 1989; 36: 299-305
10. Miehlke RK, Schneider S, Sorgel F, et al. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery. Drugs 1990; 40 Suppl. 5: 57-61
11. Haddock RE, Jeffrey DJ, Llloyd JA, et al. Metabolism of nabumetone (BRL 1477) by various species including man. Xenobiotica 1984; 14(4): 327-37
12. Von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone. A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Toxicol 1983; 21 (6): 311-21
13. Von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone. A novel anti-inflammatory drug: bioavailability after different dosage regimens. Int J Clin Pharmacol Ther Toxicol 1984; 22 (2): 672-6
14. Nandi KL, Corless D, Undre NA, et al. A study of the pharmacokinetics, effectiveness, and tolerance of nabumetone, a novel anti-inflammatory drug, in elderly patients. Roy Soc Med Int Sym Ser 1985; 69: 163-72
15. Hamdy RC, Price JD, Undre NA, et al. The pharmacokinetics of nabumetone in elderly patients. Roy Soc Med Int Sym Ser 1985; 69: 173-9
16. Boelaert JR, Jonnaert HA, Daneels RF, et al. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment. Am J Med 1987; 83 Suppl. 4B: 107-9
17. McMahon FG, Vargas R, Ryan JR. Nabumetone kinetics in the young and elderly. Am J Med 1987: 83 Suppl. 4B: 92-5
18. Terziivanov D, Maleev A, Vlahov V. Nabumetone (BRL 14777) presystemic elimination and disposition in patients with liver impairments. Int J Clin Pharmacol Ther Toxicol 1987; 25 (4): 208-13
19. Brier ME, Aronoff GR. Multiple dose kinetics of nabumetone in renal impairment [abstract]. Clin Res 1990; 38: 520
20. Brett MA, Buscher G, Ellrich E, et al. Nabumetone: evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans. Drugs 1990; 40 Suppl. 5: 67-70
21. Brier ME, Sloan RS, Aronoff GR. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clin Pharmacol Ther 1995; 57: 622-7
22. Hyneck ML. An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 20-4
23. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 1997; 32 (4): 321-5
24. Hyneck M, Audet P, Nichols A, et al. Steady-state pharmacokinetics an ex vivo protein binding of nabumetone. Clin Pharmacol Ther 1993; 53: 212 PIII-22
25. Bourke B, Undre NA, Thawley AR. An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis. Roy Soc Med Int Sym Ser 1985; 69: 31-5
26. Freeman AM, Undre NA, Thawley AR, et al. Plasma and synovial fluid concentrations of nabumetone and BRL 10720 in patients given nabumetone. Roy Soc Med Int Sym Ser 1984; 69: 40-2
27. Davies NM, Wallace JL. Non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J Gastroenterol 1997; 32 (2): 127-33
28. Blower P. The science - equivalent efficacy and diminished risk. Eur J Rheum Inflamm 1991; 11: 37-57
29. Reuter BK, Davies NM, Wallace JL. NSAID-enteropathy in rats: role of epithelial permeability, bacterial load, and enterohepatic circulation. Gastroenterology 1997; 112 (1): 109-17
30. Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32: 275-7
31. Devlin J, Moots R, Andrews D, et al. High intestinal permeability in patients with inflammatory arthritis is more strongly associated with any NSAID therapy than with diagnosis or disease activity. Arthritis Rheum 1996; S280: 1513
32. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
33. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid anti-rheumatoid drugs. Arch Toxicol 1984; 7: 315-22
34. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non- steroidal anti-inflammatory drugs. J Biol Chem 1993: 268 (9): 6610-4
35. Davies NM, Wallace JL. Selective inhibitors of cyclooxygenase 2: potential in elderly patients. Drugs Aging 1996; 9 (6): 406-17
36. Lemmel EM, Bolten W, Burgos-Vargas R, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997; 24 (2): 282-90
37. Bjarnason I, Macpherson A, Rotman H, et al. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and diclofenac. Scand J Gastroenterol 1997; 32 (2): 126-30
38. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076-85
39. Mizuno H, Sakamoto C, Matsuda K. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by specific antagonist delays healing in mice. Gastroenterology 1997; 112:387-97
40. Voss GD. GI bleeding associated with nabumetone. Am J Hosp Pharm 1994; 51: 2506-8
41. Eberhardt CE, Coffey RJ, Radhika A, et al. Up regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1996; 107: 1183-8
42. Kargman SL, ONeill GP, Vikers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colorectal cancer. Cancer Res 1991; 55: 2556-9
43. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimers disease. Neurology 1993; 43: 1609-11
44. Onoe Y, Miaura C, Kammakayashik T. IL-13 and IL-14 inhibit bone suppressing cyclooxygenase-2 prostaglandin synthesis in osteoblasts. J Immmunol 1996; 156: 758-64
45. Fitzgerald DE. Double-blind study to establish whether there is any interaction between nabumetone and warfarin in healthy adult male volunteers. Roy Soc Med In Cong Sym Ser 1985; 69: 47-53